Handelsbanken Fonder’s Soleno Therapeutics SLNO Stock Holding History

Handelsbanken Fonder’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,400	Closed	-$516K	–	1549
2026 Q1	$516K	Hold	15,400	–	–	﹤0.01%	1288
2025 Q4	$713K	Buy	15,400 +1,600	+12%	+$87.7K	﹤0.01%	1184
2025 Q3	$933K	Buy	13,800 +3,400	+33%	+$252K	﹤0.01%	1034
2025 Q2	$871K	Buy	+10,400	New	+$778K	﹤0.01%	1021

Handelsbanken Fonder's SLNO Position: Q2 2026 in Review

Handelsbanken Fonder sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 15,400 shares — an estimated $516K sold.

Handelsbanken Fonder first reported a position in SLNO in Q2 2025 and held it in 4 quarters. The position peaked at $933K in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Handelsbanken Fonder reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Handelsbanken Fonder sold 15,400 Soleno Therapeutics shares in Q2 2026, an estimated $516K.
Handelsbanken Fonder first reported a position in Soleno Therapeutics in Q2 2025 and held it in 4 quarters.
Handelsbanken Fonder's Soleno Therapeutics position peaked at $933K in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.